Skip to content

Study · Not a test of the peptide alone · 2024

4 results

Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.

Sindhu U, Sharma A, Zawar I, Punia V

Epilepsia open2 Nov 2024Cited by 23 (Europe PMC)

PMID39487832 (opens in a new tab)PMCIDPMC11633680 (opens in a new tab)DOI10.1002/epi4.13091 (opens in a new tab)PepBankPUB-39487832
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials, pooled newer glucose-lowering drugs lowered the combined risk of late-onset seizures and epilepsy versus placebo.

    In plain wordsIn pooled trials, newer diabetes drugs as a group were linked to lower risk of seizures and epilepsy than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseCombined late-onset seizures and epilepsy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    RR
    0.76
    newer GLDs vs placebo, seizures and epilepsy combined

    Source sentences

    Summary
    Patients taking newer GLDs had a 24% lower risk of late-onset seizures and epilepsy, combined, (RR: 0.76, 95% CI: 0.62-0.95)
    1 context sentence
    Summary · context
    Of them, 27 studies with almost 200 000 patients (mean age 64.9 years, 65.6% males) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials, pooled newer glucose-lowering drugs lowered the risk of late-onset seizures alone versus placebo.

    In plain wordsIn pooled trials, newer diabetes drugs as a group were linked to lower risk of seizures alone than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseLate-onset seizures only
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    RR
    0.78
    newer GLDs vs placebo, seizures only

    Source sentences

    Summary
    22% lower risk of late-onset seizures only (RR = 0.78; 95% CI = 0.60-1.00), compared to patients on placebo.
    1 context sentence
    Summary · context
    Of them, 27 studies with almost 200 000 patients (mean age 64.9 years, 65.6% males) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials, the lower seizure and epilepsy risk was seen only among patients taking GLP-1 receptor agonists as a class.

    In plain wordsIn pooled trials, the lower seizure and epilepsy risk was seen only with the GLP-1 drug class, not with other newer diabetes drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseSeizure and epilepsy prevention by GLP-1 receptor agonists
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    This seizure and epilepsy prevention benefit was only noted among patients taking GLP-1 receptor agonists.
    1 context sentence
    Summary · context
    Of them, 27 studies with almost 200 000 patients (mean age 64.9 years, 65.6% males) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials, stroke incidence with pooled newer glucose-lowering drugs was comparable to placebo.

    In plain wordsIn pooled trials, newer diabetes drugs as a group did not change stroke rates compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeStroke incidence
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Stroke incidence was comparable between newer GLDs and placebo group.
    1 context sentence
    Summary · context
    Of them, 27 studies with almost 200 000 patients (mean age 64.9 years, 65.6% males) were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.